Sugi Predict

Sugi Predict / Compounds / Ip-2018

Ip-2018

Ip-2018

SCHEMBL1103728

O=c1ccc2ccc(O[C@@H]3C[C@H]4CC[C@@H](C3)N4)cc2o1

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A4 P31645 13/20 0.59
▸ SLC6A2 P23975 10/20 0.59
▸ SLC6A3 Q01959 10/20 0.59
▸ MAOA P21397 1/20 0.54
▸ KDM4E B2RXH2 3/20 0.50
▸ CA12 O43570 3/20 0.50
▸ CA9 Q16790 3/20 0.50
▸ ALDH1A1 P00352 2/20 0.50
▸ CA1 P00915 2/20 0.50
▸ CA4 P22748 2/20 0.50
▸ CA6 P23280 2/20 0.50
▸ CA5A P35218 2/20 0.50
▸ CA7 P43166 2/20 0.50
▸ CA14 Q9ULX7 2/20 0.50
▸ CA3 P07451 1/20 0.50
▸ AKR1B1 P15121 1/20 0.50
▸ HPGD P15428 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ GLA P06280 3/20 0.48
▸ GAA P10253 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ip-2018 SCHEMBL26041644 1.00 SLC6A4 (0.59) SLC6A4SLC6A2SLC6A3MAOAKDM4E
Ip-2018 SCHEMBL25368803 1.00 SLC6A4 (0.59) SLC6A4SLC6A2SLC6A3MAOAKDM4E
Ip-2018 SCHEMBL2191263 0.99 SLC6A4 (0.58) SLC6A4SLC6A2SLC6A3MAOAKDM4E
SCHEMBL1951771 0.95 MAOA (0.55) SLC6A4SLC6A2SLC6A3MAOAKDM4E
Hydrochloric Acid SCHEMBL1952032 0.94 MAOA (0.54) SLC6A4SLC6A2SLC6A3MAOAKDM4E
SCHEMBL4444784 0.88 SLC6A4 (0.59) SLC6A4SLC6A2SLC6A3MAOAKDM4E
SCHEMBL13614586 0.83 MAOA (0.56) MAOAKDM4ECA12CA9ALDH1A1
SCHEMBL12337641 0.83 MAOA (0.56) MAOAKDM4ECA12CA9ALDH1A1
SCHEMBL742602 0.82 SLC6A4 (0.82) SLC6A4SLC6A2SLC6A3MAOA
SCHEMBL15304588 0.82 SLC6A4 (0.82) SLC6A4SLC6A2SLC6A3MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025051846-A1 COMPOUND FOR TREATMENT OF FEMALE SEXUAL DYSFUNCTION INITIATOR PHARMA A/S (DK) 2025-03-13 — — WO disclosed
EP-4241839-A2 COMPOUND FOR COMBINATION TREATMENT Initiator Pharma A/S (DK) 2023-09-13 — — EP disclosed
EP-4241839-A2 COMPOUND FOR COMBINATION TREATMENT Initiator Pharma A/S (DK) 2023-09-13 — — EP disclosed
EP-4225681-A1 SHEET FEEDING DEVICE AND IMAGE FORMING SYSTEM INCORPORATING THE SHEET FEEDING DEVICE Ricoh Company, Ltd. (JP) 2023-08-16 — — EP disclosed
EP-4009942-B1 COMPOUND FOR COMBINATION TREATMENT INITIATOR PHARMA AS (DK) 2023-08-09 — — EP disclosed
CN-115867561-A Expression of SARS-CoV proteins, nucleic acid constructs, virus-like proteins (VLPs), and methods related thereto 普瑞玛斯生物技术私人有限公司 2023-03-28 — — CN disclosed
WO-2023037158-A1 PROCESS FOR PREPARATION OF CRYSTALLINE FLUORESCEIN SODIUM FROM DIACETYLFLUORESCEIN OR FLUORESCEIN MACSEN DRUGS (IN) 2023-03-16 — — WO disclosed
US-20220288052-A1 COMPOUND FOR COMBINATION TREATMENT INITIATOR PHARMA A/S (DK) 2022-09-15 — — US disclosed
EP-4009942-A1 COMPOUND FOR COMBINATION TREATMENT Initiator Pharma A/S (DK) 2022-06-15 — — EP disclosed
CN-114430679-A Compounds for combination therapy 创始人制药股份有限公司 2022-05-03 — — CN disclosed
WO-2022079531-A1 SHEET FEEDING DEVICE AND IMAGE FORMING SYSTEM INCORPORATING THE SHEET FEEDING DEVICE RICOH COMPANY, LTD. (JP) 2022-04-21 — — WO disclosed
WO-2021023805-A1 COMPOUND FOR COMBINATION TREATMENT INITIATOR PHARMA A/S (DK) 2021-02-11 — — WO disclosed
US-8153797-B2 Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2012-04-10 — — US disclosed
US-7994323-B2 Chromen-2-one derivatives NEUROSEARCH A/S (DK) 2011-08-09 — — US disclosed
US-7994323-B2 Chromen-2-one derivatives NEUROSEARCH A/S (DK) 2011-08-09 — — US disclosed
EP-2158200-B1 NOVEL CHROMEN-2-ONE DERIVATIVES NEUROSEARCH AS (DK) 2011-07-13 — — EP disclosed
US-20100227883-A1 NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS ANIONA APS (DK) 2010-09-09 — — US disclosed
US-20100217002-A1 NOVEL CHROMEN-2-ONE DERIVATIVES NEUROSEARCH A/S (DK) 2010-08-26 — — US disclosed
US-20100217002-A1 NOVEL CHROMEN-2-ONE DERIVATIVES NEUROSEARCH A/S (DK) 2010-08-26 — — US disclosed
WO-2008138854-A1 NOVEL CHROMEN-2-ONE DERIVATIVES NEUROSEARCH A/S (DK) 2008-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220288052-A1 COMPOUND FOR COMBINATION TREATMENT PDE3B, PDE2A, PDE3A SLC6A4 50/4885SLC6A2 33/4885SLC6A3 57/4885
US-20100227883-A1 NOVEL CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS SLC6A2, SLC18A2, SLC18A1 SLC6A4 5/4885SLC6A2 1/4885SLC6A3 8/4885
US-20100217002-A1 NOVEL CHROMEN-2-ONE DERIVATIVES CBX2, CYP2J2, CDYL2 SLC6A4 3442/4885SLC6A2 2618/4885SLC6A3 4387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.